gemcitabine has been researched along with masitinib in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bader, T; Bertucci, F; Castéran, N; Dubreuil, P; Finetti, P; Hanssens, K; Hermine, O; Humbert, M; Iovanna, J; Letard, S; Mansfield, CD; Moussy, A | 1 |
| Deplanque, G; Hammel, P; Hermine, O; Kinet, JP; Levy, P; Mitry, E; Mornex, F; Moussy, A; Raymond, E; Rougier, P; Seitz, JF | 1 |
| Dubreuil, P; Hermine, O; Humbert, M; Kow, K; Mansfield, CD; Moussy, A; Rose, B; Thamm, DH | 1 |
| Acin, Y; Atkins, J; Demarchi, M; Deplanque, G; Dubreuil, P; Flynn, P; Hammel, P; Hebbar, M; Hermine, O; Mansfield, CD; Melichar, B; Moussy, A; Moyé, L; Nowara, E; Piquemal, D; Ritter, D | 1 |
| Avallone, A; Botti, G; Capozzi, M; De Divitiis, C; De Stefano, A; Ottaiano, A; Tafuto, S | 1 |
| Audebert, S; Baudelet, E; Betzi, S; Casteran, N; Combes, S; De Sepulveda, P; Dubreuil, P; Gros, L; Hajem, B; Hammam, K; Humbert, M; Letard, S; Lopez, S; Lugari, A; Mansfield, C; Morelli, X; Moussy, A; Rebuffet, E; Saez-Ayala, M | 1 |
1 review(s) available for gemcitabine and masitinib
| Article | Year |
|---|---|
Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Piperidines; Pyridines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles | 2017 |
2 trial(s) available for gemcitabine and masitinib
| Article | Year |
|---|---|
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Endpoint Determination; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Piperidines; Pyridines; Survival Analysis; Thiazoles | 2010 |
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Oxidoreductases; Pancreatic Neoplasms; Pharmacogenetics; Piperidines; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; United States | 2015 |
4 other study(ies) available for gemcitabine and masitinib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Piperidines; Pyridines; Thiazoles | 2010 |
Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Deoxycytidine; Dog Diseases; Dogs; Doxorubicin; Drug Synergism; Gemcitabine; Inhibitory Concentration 50; Piperidines; Protein Kinase Inhibitors; Pyridines; Sarcoma; Thiazoles; Vinblastine | 2012 |
Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.
Topics: A549 Cells; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Crystallography, X-Ray; Deoxycytidine; Deoxycytidine Kinase; Drug Design; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; Humans; Imatinib Mesylate; Models, Biological; Models, Molecular; Phosphorylation; Piperidines; Polypharmacology; Protein Kinase Inhibitors; Proteomics; Pyridines; Thiazoles | 2017 |